Related Experiment Video

Updated: Aug 23, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Epidermal growth factor receptor as a target to improve treatment of lung cancer

Nicolaus H Andratschke1, Klaus H Dittmann, Kathryn A Mason

  • 1Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.

Clinical Lung Cancer
|June 26, 2004
PubMed

Insights

Targeting the epidermal growth factor receptor (EGFR) shows promise for improving outcomes in non-small-cell lung cancer (NSCLC). Research explores blocking EGFR signaling alone or with chemotherapy and radiation for better lung cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer remains a leading cause of cancer death globally.
  • Locally advanced non-small-cell lung cancer (NSCLC) still has poor patient survival rates despite treatment advances.
  • Aberrant molecular pathways are increasingly targeted for cancer therapy.

Purpose of the Study:

  • To review the role of epidermal growth factor receptor (EGFR) in lung cancer development and progression.
  • To summarize preclinical and clinical data on strategies targeting EGFR signaling in NSCLC.
  • To evaluate EGFR-targeted therapies as single agents or in combination with chemotherapy and/or radiation.

Main Methods:

  • Review of existing literature on EGFR in lung cancer.
  • Analysis of preclinical studies investigating EGFR inhibitors.
  • Examination of clinical trial data for EGFR-targeted therapies in NSCLC.

Main Results:

  • Epidermal growth factor receptor (EGFR) is frequently overexpressed in NSCLC, especially squamous cell carcinoma.
  • Various strategies to block EGFR signaling have been developed and studied.
  • Combinations of EGFR inhibitors with chemotherapy or radiation are under investigation.

Conclusions:

  • Targeting EGFR signaling is a key area of research for NSCLC treatment.
  • Further investigation into EGFR-targeted therapies, alone or in combination, is warranted.
  • These approaches may offer improved survival for patients with locally advanced NSCLC.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...